Subcutaneous Vs Sublingual Immunotherapy for Adults with All
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
According to researchers, both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are effective in adults with allergic rhinitis or rhinoconjunctivitis (AR/C). The research has been published in The Laryngoscope.

The study objective was to determine whether SCIT or SLIT better improves patient outcomes and quality of life for adults with allergic rhinitis or rhinoconjunctivitis (AR/C) with or without mild to moderate asthma.

Four databases (PubMed, Cochrane Library, EMBASE, and Web of Science) were queried. Two independent reviewers screened potentially relevant studies and assessed the risk of bias. Outcomes of interest were symptom score (SS), medication score (MS), combined symptom medication score (CSMS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

Seven SCIT versus SLIT RCTs demonstrated no significant differences for any outcomes, but insufficient data precluded direct meta?analysis. For the adjusted indirect comparison, 46 RCTs over 39 studies were included for SCIT versus placebo and SLIT versus placebo. Statistically significant results favoring SCIT were found for SS, MS, CSMS, and RQLQ. Statistically significant results favoring SLIT were found for SS, MS, CSMS, and RQLQ. No significant differences were found between SCIT and SLIT for SS, MS, CSMS, or RQLQ.

Conclusively, SCIT and SLIT are comparably effective treatments for adults with AR/C.

Source: https://doi.org/10.1002/lary.29586
Like
Comment
Share